IQVIA Holdings Inc. $IQV Holdings Trimmed by Eagle Rock Investment Company LLC

Eagle Rock Investment Company LLC decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.9% during the 3rd quarter, Holdings Channel reports. The firm owned 57,338 shares of the medical research company’s stock after selling 4,220 shares during the quarter. IQVIA makes up 1.8% of Eagle Rock Investment Company LLC’s investment portfolio, making the stock its 15th biggest holding. Eagle Rock Investment Company LLC’s holdings in IQVIA were worth $15,415,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Pension & Wealth Management Advisors Inc. bought a new stake in IQVIA during the 3rd quarter worth approximately $30,000. Compass Financial Management LLC acquired a new stake in shares of IQVIA in the second quarter valued at approximately $27,000. Financial Freedom LLC bought a new position in IQVIA in the 1st quarter valued at $25,000. Ascentis Independent Advisors bought a new stake in shares of IQVIA during the first quarter worth $25,000. Finally, Elevation Wealth Partners LLC lifted its stake in shares of IQVIA by 218.8% during the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 105 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 15,581 shares of company stock valued at $3,796,021. Insiders own 1.70% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of a number of research reports. Weiss Ratings upgraded shares of IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. Stifel Nicolaus upped their price objective on IQVIA from $276.00 to $303.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. William Blair upgraded IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Morgan Stanley upped their target price on shares of IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, September 17th. Finally, Truist Financial restated a “buy” rating and issued a $329.00 price objective (up from $300.00) on shares of IQVIA in a research report on Monday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $276.00.

IQVIA Stock Performance

Shares of IQV opened at $276.56 on Thursday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $277.40. The firm has a fifty day simple moving average of $262.40 and a 200 day simple moving average of $215.24. The stock has a market capitalization of $45.52 billion, a price-to-earnings ratio of 23.58, a PEG ratio of 2.35 and a beta of 1.17.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The business’s revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 11.55 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.